Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 9/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | NPC1 | O15118 | 2/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.75 |
| ▸ | RAB9A | P51151 | 2/20 | 0.75 |
| ▸ | AURKA | O14965 | 1/20 | 0.75 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.75 |
| ▸ | JAK2 | O60674 | 1/20 | 0.75 |
| ▸ | GMNN | O75496 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | EGFR | P00533 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | LYN | P07948 | 1/20 | 0.75 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936061 | 1.00 | KCNMA1 (0.78) | KCNMA1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL8055503 | 0.90 | KMT2A (0.68) | KCNMA1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL29617487 | 0.89 | KMT2A (0.88) | KCNMA1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL22032660 | 0.89 | KMT2A (0.88) | KCNMA1MAPTKMT2AMEN1NPC1 | |
| Niclosamide SCHEMBL19856545 | 0.88 | LMNA (0.80) | KCNMA1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL22007921 | 0.87 | MEN1 (0.64) | KCNMA1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL6816172 | 0.86 | MAPT (0.71) | KCNMA1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL29936128 | 0.86 | MAPT (0.66) | KCNMA1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL8058544 | 0.86 | MAPT (0.66) | KCNMA1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL30771742 | 0.86 | KMT2A (0.81) | KCNMA1MAPTKMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102834116-B | The treatment of WNT/ FZ relevant disease | DUKE UNIVERSITY (US) | 2015-09-16 | — | — | CN | claimed |
| US-20230044449-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE AS CONTRACEPTIVE | YOURCHOICE THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230040597-A1 | USE OF NICOLSAMIDE FORMULATIONS FOR ANTIVIRAL THERAPY | YOURCHOICE THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| CN-107434770-B | P-nitroaniline compound and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2021-04-13 | — | — | CN | disclosed |
| CN-111518147-A | Benzoylanilide compound and application thereof in preparing sensitizer of pseudomonas aeruginosa inhibitor | 华东理工大学 | 2020-08-11 | — | — | CN | disclosed |
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| CN-107434770-A | P-nitrophenyl amine compound and its preparation method and pharmaceutical composition and purposes | 中国医学科学院药物研究所 | 2017-12-05 | — | — | CN | disclosed |
| CN-106999505-A | The antibacterial application of halo salicylanilide | 安蒂比奥特克斯有限公司 | 2017-08-01 | — | — | CN | disclosed |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-20130150416-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD D (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130005802-A1 | TREATMENT OF WNT/FRIZZLED-RELATED DISEASES | DUKE UNIVERSITY | 2013-01-03 | — | — | US | disclosed |
| US-20130005802-A1 | TREATMENT OF WNT/FRIZZLED-RELATED DISEASES | DUKE UNIVERSITY | 2013-01-03 | — | — | US | disclosed |
| US-8211882-B2 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211882-B2 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211882-B2 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY (US) | 2012-07-03 | — | — | US | disclosed |
| WO-2010101648-A1 | GLUTAMATE RECEPTOR MODULATORS AND THERAPEUTIC AGENTS | WOOD RICHARD D (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY | 2009-09-24 | — | — | US | disclosed |
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY | 2009-09-24 | — | — | US | disclosed |
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | GLS2, PC, GLS | KCNMA1 2695/4885MAPT 2394/4885KMT2A 1812/4885 |
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | GRM5, GRM1, GRIK5 | KCNMA1 563/4885MAPT 4555/4885KMT2A 881/4885 |
| US-20130005802-A1 | TREATMENT OF WNT/FRIZZLED-RELATED DISEASES | WNT1, WNT3, SFRP1 | KCNMA1 2269/4885MAPT 1012/4885KMT2A 1713/4885 |
| US-20130150416-A1 | Glutamate receptor modulators and therapeutic agents | GRM5, GRM1, GRIK5 | KCNMA1 375/4885MAPT 3727/4885KMT2A 454/4885 |
| US-20230044449-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE AS CONTRACEPTIVE | NCSTN, SHBG, LPXN | KCNMA1 2803/4885MAPT 2603/4885KMT2A 2937/4885 |
| US-20230040597-A1 | USE OF NICOLSAMIDE FORMULATIONS FOR ANTIVIRAL THERAPY | NAPRT, NIT2, NNT | KCNMA1 2139/4885MAPT 1330/4885KMT2A 2696/4885 |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | GLS2, PC, GLS | KCNMA1 2695/4885MAPT 2394/4885KMT2A 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.